m+Medelevator.RU
← Поиск публикаций
Frontiers in human neuroscience · 2025

Proceedings of the 12th annual deep brain stimulation think tank: cutting edge technology meets novel applications.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Martinez-Nunez Alfonso Enrique, Rozell Christopher J, Little Simon, Tan Huiling, Schmidt Stephen L, Grill Warren M, Pajic Miroslav, Turner Dennis A, de Hemptinne Coralie, Machado Andre, Schiff Nicholas D, Holt-Becker Abbey S, Raike Robert S, Malekmohammadi Mahsa, Pathak Yagna J, Himes Lyndahl, Greene David, Krinke Lothar, Arlotti Mattia, Rossi Lorenzo, Robinson Jacob, Bahners Bahne H, Litvak Vladimir, Milosevic Luka, Ghatan Saadi, Schaper Frederic L W V J, Fox Michael D, Gregg Nicholas M, Kubu Cynthia, Jordano James J, Cascella Nicola G, Nho YoungHoon, Halpern Casey H, Mayberg Helen S, Choi Ki Sueng, Song Haneul, Cha Jungho, Alagapan Sankaraleengam, Dosenbach Nico U F, Gordon Evan M, Ren Jianxun, Liu Hesheng, Kalia Lorraine V, Hescham Sarah-Anna, Kusyk Dorian M, Ramirez-Zamora Adolfo, Foote Kelly D, Okun Michael S, Wong Joshua K

Аннотация

The Deep Brain Stimulation (DBS) Think Tank XII was held on August 21st to 23rd. This year we showcased groundbreaking advancements in neuromodulation technology, focusing heavily on the novel uses of existing technology as well as next-generation technology. Our keynote speaker shared the vision of using neuro artificial intelligence to predict depression using brain electrophysiology. Innovative applications are currently being explored in stroke, disorders of consciousness, and sleep, while established treatments for movement disorders like Parkinson's disease are being refined with adaptive stimulation. Neuromodulation is solidifying its role in treating psychiatric disorders such as depression and obsessive-compulsive disorder, particularly for patients with treatment-resistant symptoms. We estimate that 300,000 leads have been implanted to date for neurologic and neuropsychiatric indications. Magnetoencephalography has provided insights into the post-DBS physiological changes. The field is also critically examining the ethical implications of implants, considering the long-term impacts on clinicians, patients, and manufacturers.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты